Stakeholders concurred that the occurrence of VTE events is a significant public health concern. According to Ralph J. Riello III, PharmD, “It is a problem often that hospitals do not know that they ...
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...
A secondary analysis of the CLEAR Outcomes trial has found that bempedoic acid (Nexletol) was associated with a reduced risk of venous thromboembolism (VTE). The findings suggest that, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results